ES2351581T3 - Análogos del apogosipol para su utilización en el tratamiento del cáncer. - Google Patents

Análogos del apogosipol para su utilización en el tratamiento del cáncer. Download PDF

Info

Publication number
ES2351581T3
ES2351581T3 ES08003839T ES08003839T ES2351581T3 ES 2351581 T3 ES2351581 T3 ES 2351581T3 ES 08003839 T ES08003839 T ES 08003839T ES 08003839 T ES08003839 T ES 08003839T ES 2351581 T3 ES2351581 T3 ES 2351581T3
Authority
ES
Spain
Prior art keywords
alkyl
cancer
group
toxin
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES08003839T
Other languages
English (en)
Spanish (es)
Inventor
John C. Reed
Maurizio Pellecchia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Application granted granted Critical
Publication of ES2351581T3 publication Critical patent/ES2351581T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES08003839T 2003-06-25 2004-06-25 Análogos del apogosipol para su utilización en el tratamiento del cáncer. Expired - Lifetime ES2351581T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48288603P 2003-06-25 2003-06-25
US482886P 2003-06-25

Publications (1)

Publication Number Publication Date
ES2351581T3 true ES2351581T3 (es) 2011-02-08

Family

ID=34102647

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08003839T Expired - Lifetime ES2351581T3 (es) 2003-06-25 2004-06-25 Análogos del apogosipol para su utilización en el tratamiento del cáncer.
ES04777151T Active ES2303096T7 (es) 2003-06-25 2004-06-25 Derivados del catecol para el tratamiento del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04777151T Active ES2303096T7 (es) 2003-06-25 2004-06-25 Derivados del catecol para el tratamiento del cancer.

Country Status (13)

Country Link
US (3) US7812058B2 (https=)
EP (2) EP1938816B1 (https=)
JP (2) JP2007524633A (https=)
AT (2) ATE478663T1 (https=)
AU (1) AU2004258867B2 (https=)
CA (1) CA2529507C (https=)
DE (2) DE602004012279T3 (https=)
DK (1) DK1653943T4 (https=)
ES (2) ES2351581T3 (https=)
PL (1) PL1653943T6 (https=)
PT (1) PT1653943E (https=)
SI (1) SI1653943T1 (https=)
WO (1) WO2005009434A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
AU2002360335A1 (en) * 2001-11-01 2003-05-12 The Regents Of The University Of Michigan Small molecule inhibitors targeted at bcl-2
DE602004012279T3 (de) 2003-06-25 2010-07-15 The Burnham Institute, La Jolla Katecholderivate zur behandlung von krebs
EA011218B1 (ru) 2004-03-25 2009-02-27 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Сокристаллы госсипола и их применение
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
WO2009045410A1 (en) * 2007-10-01 2009-04-09 Ascenta Therapeutics, Inc. Process for preparing r-gossypol l-phenylalaninol dienamine
AU2008311827A1 (en) * 2007-10-19 2009-04-23 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
FR2924712B1 (fr) 2007-12-06 2012-12-21 Univ Maine Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications
GB0725077D0 (en) * 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
WO2009126172A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University In The City Of New York Resistance to polyphenon e due to increased bcl-2 expression
US20110144125A1 (en) * 2008-08-14 2011-06-16 The Uab Research Foundation Anti-Arrhythmia Agents, Methods of Their Use, Methods of Their Identification and Kits Therefore
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
BRPI1016102A2 (pt) 2009-04-15 2015-09-01 Sanford Burhnham Medical Res Inst Inibidores de proteínas anti-apoptótica baseados em naftaleno
WO2011017096A2 (en) * 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
KR20120060234A (ko) 2009-10-08 2012-06-11 샌포드-번햄 메디칼 리서치 인스티튜트 항암제로서의 아포고시폴론 유도체
EP2956470A4 (en) * 2013-02-15 2016-12-07 Univ Michigan Regents COMPOSITIONS AND METHODS RELATED TO PREVENTING DOT1L RECRUITMENT BY MLL FUSION PROTEINS
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US9750716B2 (en) * 2015-03-19 2017-09-05 Wendy Anne Epstein Compounds and forms of treatment for female sexual disorders
RU2654711C1 (ru) * 2017-07-10 2018-05-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, обладающее апоптоз-индуцирующей активностью
KR102432499B1 (ko) * 2018-04-20 2022-08-12 나이키 이노베이트 씨.브이. 플레이트들 및 개재된 유체 충전 블래더를 구비하는 솔 구조체 및 제조 방법
CN110128290B (zh) * 2019-05-10 2022-04-29 江苏耐雀生物工程技术有限公司 红倍酚苯甲酰肼衍生物、中间体、制备方法及其应用
CA3155694A1 (en) * 2019-09-24 2021-04-01 Genetec Inc. Intermediary device for daisy chain and tree configuration in hybrid data/power connection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US5804567A (en) * 1996-07-18 1998-09-08 Cancer Institute (Hospital), Chinese Academy Of Medical Sciences Method of increasing the effectiveness of anti-metabolites
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
WO2002047673A2 (en) * 2000-12-15 2002-06-20 Wackvom Limited Methods and compositions to treat conditions associated with neovascularization
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
AU2002305769B2 (en) * 2001-05-30 2007-07-19 Georgetown University Small molecule antagonists of Bcl2 family proteins
DE602004012279T3 (de) * 2003-06-25 2010-07-15 The Burnham Institute, La Jolla Katecholderivate zur behandlung von krebs

Also Published As

Publication number Publication date
DE602004012279T2 (de) 2009-07-16
ATE387911T1 (de) 2008-03-15
EP1938816A2 (en) 2008-07-02
EP1653943B3 (en) 2008-07-30
AU2004258867A1 (en) 2005-02-03
EP1938816A3 (en) 2008-08-06
SI1653943T1 (sl) 2008-08-31
DE602004012279D1 (de) 2008-04-17
DK1653943T4 (da) 2008-12-01
DE602004012279T9 (de) 2010-01-28
JP2007524633A (ja) 2007-08-30
US20120269901A1 (en) 2012-10-25
EP1938816B1 (en) 2010-08-25
CA2529507A1 (en) 2005-02-03
PL1653943T3 (pl) 2008-09-30
PT1653943E (pt) 2008-05-23
DK1653943T3 (da) 2008-06-23
EP1653943A2 (en) 2006-05-10
WO2005009434A3 (en) 2005-06-09
ES2303096T7 (es) 2009-06-18
US8367644B2 (en) 2013-02-05
ATE478663T1 (de) 2010-09-15
ES2303096T3 (es) 2008-08-01
PL1653943T6 (pl) 2009-02-27
US20050027000A1 (en) 2005-02-03
CA2529507C (en) 2011-08-09
JP2012025767A (ja) 2012-02-09
WO2005009434A2 (en) 2005-02-03
US7812058B2 (en) 2010-10-12
DE602004028880D1 (de) 2010-10-07
US20110111057A1 (en) 2011-05-12
DE602004012279T3 (de) 2010-07-15
AU2004258867B2 (en) 2010-02-18
EP1653943B1 (en) 2008-03-05

Similar Documents

Publication Publication Date Title
ES2351581T3 (es) Análogos del apogosipol para su utilización en el tratamiento del cáncer.
Dei et al. Recent advances in the search of BCRP-and dual P-gp/BCRP-based multidrug resistance modulators
US7776894B2 (en) Compositions and methods for inhibiting growth and metastasis of melanoma
US20240342199A1 (en) Combination therapies targeting mitochondria for cancer therapy
ES2287029T3 (es) Composicion y procedimiento para modular la apoptosis en celulas que sobreexpresan proteinas miembro de la familia bcl-2.
US20050239873A1 (en) 2 Methoxy antimycin a derivatives and methods of use
CN110088210A (zh) 与酪氨酸激酶抑制剂结合使用的癌细胞增敏剂和增敏方法
Aneja et al. Rational design of the microtubule-targeting anti–breast cancer drug EM015
WO2012064897A2 (en) Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
AU2016298175B2 (en) Compositions and methods of treating cancer
ES2763156T3 (es) Inducción apoptótica selectiva en células cancerosas incluyendo la activación de procaspasa-3
US7652033B2 (en) HIF-1 inhibitors
US20240207258A1 (en) Heterocyclic pdk1 inhibitors for use to treat cancer
CN106029070A (zh) 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途
BRPI0708307A2 (pt) combinação farmacêutica para administração simultánea, separada ou sequencial e usos de combinações farmacêuticas e de um inibidor do sìtio de fosforilação sobre os substratos de ck2 e um citostático farmaceuticamente aceitável
Niu et al. Novel carbazole sulfonamide microtubule-destabilizing agents exert potent antitumor activity against esophageal squamous cell carcinoma
AU731125B2 (en) Method for inducing death of neoplastic cells using piperazine oxirane derivatives
US11512073B2 (en) Benzimidazole derivatives, pharmaceutical composition comprising the same, and use thereof
Meng et al. Direct targeting of GLUT1 in cancer: A decade of inhibitor discovery and medicinal chemistry insights
US20260083724A1 (en) Compounds targeting pax3::foxo1 fusion protein
Scarpecci et al. Biological Activities of Synthetic Derivatives of Xanthones: An Update (2016-2020)
AU2015101721A4 (en) Prenylated isoflavones for treatment of subjects with multidrug-resistant cancer
WO2013028866A1 (en) Therapeutic compounds and methods
EP3600433A1 (en) An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
HK1259985A1 (en) Heterocyclic pdk1 inhibitors for use to treat cancer